Our Strategy
Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity. Our portfolio of investigational spleen tyrosine kinase (SYK) inhibitors are being developed to treat certain genetic subtypes of acute myeloid leukemia, one of the most difficult-to-treat blood cancers. We are also developing KB-0742, a selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) for the treatment of MYC-dependent solid tumors. In addition, we have multiple oncology discovery programs targeting dysregulated transcription factors.
Our Science
Targeting dysregulated transcription factors in cancer
Addressing the complexity of oncogenic TRNs requires a sophisticated and holistic approach to targeting cancer biology. TRNs encompass hundreds of proteins that function in a coordinated fashion to orchestrate specific gene expression programs that control development and function of healthy cells. Dysregulated TRNs resulting from aberrant transcription factor expression or activity are frequently responsible for reprogramming healthy cells into cancerous tumor cells. We apply computational biology to map the TRNs and identify the critical nodes and gene expression signatures that drive cancer. We believe that these critical nodes present attractive targets for therapeutic intervention using a biomarker-driven precision medicine strategy.
Product Engine
Our product engine includes four interconnected components, each of which is informed by our translational expertise, that enable efficient, hypothesis-driven clinical development of our product candidates:
Identify gene expression signature of selective TRN modulation
Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators
Refine pharmacological properties to yield attractive product development candidates
Hypothesis driven clinical trials to deliver proof of concept early in the development process
Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators
Hypothesis driven clinical trials to deliver proof of concept early in the development process
Pipeline/Programs
We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline, including our lead product candidate, ENTO, as well as our discovery programs and our next anticipated milestones.
TRN
Investigational Therapy
Discovery
IND-Enabling Studies
Phase 1 Trial
Phase 2 Trial
Phase 3 Trial
Mid 2021: Initiate Registrational Phase 3 clinical trial
Late 2021: Initiate Phase 1/2 clinical trial in combination with gilteritinib
Early 2022: Initiate Phase 1/2 clinical trial in combination with venetoclax/azacitidine
Q4 2021: Initial safety, PK and PD data from Phase 1/2 clinical trial dose escalation cohorts
*We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.
Careers
JOIN OUR TEAM
We are looking for innovative team members who share our passion for transformative science paired with unparalleled execution.
See our current list of openings below or submit your resume to careers@kronosbio.com.
“
we’re building the highway, not filling potholes”
‟we’re building the highway, not filling potholes”
Director, Biology